Sickle Cell Disease Trial, Recruiting (NCT05153967)

Sickle Cell Disease Trial, Recruiting NCT05153967 Sponsor: Vanderbilt University Medical Center Condition: Sickle Cell Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05153967 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sickle Cell Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with Sickle Cell Disease (SCD) confirmed by a laboratory test
You are able to understand and sign a consent form agreeing to take part in the study
You are able to provide medical records or data from both before and after your treatment
You have been treated with either a stem cell transplant (a procedure where diseased bone marrow is replaced with healthy donor cells) or with standard medications used to manage Sickle Cell Disease

Who may not be able to join:

You have a history of not following through with medical treatments or study requirements as instructed by your healthcare team

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael R DeBaun, MD, MPH, Vanderbilt University Medical Center

Phone: 6158751992

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05153967

Sponsor: Vanderbilt University Medical Center

Phase: Not Applicable

Status: Recruiting

Condition: Sickle Cell Disease

Trial contact: 6158751992

More information: https://clinicaltrials.gov/study/NCT05153967

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with Sickle Cell Disease (SCD) confirmed by a laboratory test
You are able to understand and sign a consent form agreeing to take part in the study
You are able to provide medical records or data from both before and after your treatment
You have been treated with either a stem cell transplant (a procedure where diseased bone marrow is replaced with healthy donor cells) or with standard medications used to manage Sickle Cell Disease

Who may not be able to join:

You have a history of not following through with medical treatments or study requirements as instructed by your healthcare team

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Vanderbilt University Medical Center

Registry

ClinicalTrials.gov

Start date

12 July 2022

Est. completion

1 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Measurement of longitudinal change in FEV1; Percent predicted value of longitudinal change in FEV1; Measurement of longitudinal change in FVC; Percent predicted value of longitudinal change in FVC; FEV1/FVC Ratio Percentage; Longitudinal change in eGFR; Longitudinal change in albuminuria levels; Longitudinal change in TRJV in adults with SCD treated with nonmyeloablative allo HSCT in adults; Longitudinal change in SBP/DBP in adults with SCD treated with nonmyeloablative allo HSCT in adults

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov